Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Osimertinib (Tagrisso) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC).

Osimertinib (Tagrisso) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) - Repository of AIHTA GmbH English | Browse - - - Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult (...) patients with stage IB-IIIA non-small cell lung cancer (NSCLC) Grössmann, N. (2021): Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 48. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 73kB Item Type: Oncology Fact Sheet Subjects: > > > Language: English Series Name: Oncology Fact Sheet Nr. 48 Deposited on: 17 May 2021

2021 Austrian Institute of Health Technology Assessment

2. Ramucirumab (Cyramza) - metastatic non-small cell lung cancer

Ramucirumab (Cyramza) - metastatic non-small cell lung cancer Published 07 June 2021 Statement of advice SMC2291 ramucirumab 10 mg/mL concentrate for solution for infusion (Cyramza®) Eli Lilly & Company Limited 7 May 2021 ADVICE: in the absence of a submission from the holder of the marketing authorisation ramucirumab (Cyramza®) is not recommended for use within NHSScotland. Indication under review: in combination with erlotinib for the first-line treatment of adult patients with metastatic non (...) -small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation

2021 Scottish Medicines Consortium

3. Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer Atezolizumab monotherapy for untreated advanced non- small-cell lung cancer T echnology appraisal guidance Published: 2 June 2021 www.nice.org.uk/guidance/ta705 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705) © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 16Contents Contents 1 Recommendations 4 2 Information about atezolizumab 5 Marketing authorisation

2021 National Institute for Health and Clinical Excellence - Technology Appraisals

4. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50 Full Text available with Trip Pro

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50 Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID (...) of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Apr 19;JCO2100174. doi: 10.1200/JCO.21.00174. Online ahead of print. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50 , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Lung Clinic Grosshansdorf, Airway

2021 EvidenceUpdates

5. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 Full Text available with Trip Pro

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account info Close Account Logged (...) Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212. Epub 2021 Mar 8. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Winship Cancer Institute of Emory University, Atlanta, GA. 2 Samsung Medical Center, Sungkyunkwan University School

2021 EvidenceUpdates

6. Atezolizumab (Tecentriq) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) - Repository of AIHTA GmbH English | Browse - - - Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) Grössmann, N. (2021 (...) ): Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 45. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 761kB Item Type: Oncology Fact Sheet Subjects: > > > Language: English Series Name: Oncology Fact Sheet Nr. 45 Deposited on: 16 Apr 2021 13:15 Last Modified: 16 Apr 2021 13:15 Repository Staff Only: © Copyright ,

2021 Austrian Institute of Health Technology Assessment

7. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights

Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account info Close Account Logged in as: username Search (...) Cite Display options Display options Format Share Permalink Copy Page navigation Randomized Controlled Trial Am J Respir Crit Care Med Actions . 2021 Mar 15;203(6):737-745. doi: 10.1164/rccm.202006-2359OC. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Sciences Centre. 2 Manchester University National Health

2021 EvidenceUpdates

8. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clinical Trial Lancet Oncol Actions . 2021 Mar;22(3):321-331. doi: 10.1016/S1470-2045(20)30742-7. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial , , , , , , , , , , , , Affiliations Expand

2021 EvidenceUpdates

9. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors

Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account info Close (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Thromb Haemost Actions . 2021 Feb 18. doi: 10.1111/jth.15272. Online ahead of print. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel. 2 Sackler School

2021 EvidenceUpdates

10. Recommendations for the Management of Actionable Incidental Findings in the Lung Cancer Screening Pilot for People at High Risk

Recommendations for the Management of Actionable Incidental Findings in the Lung Cancer Screening Pilot for People at High Risk 525 University Avenue, 5th Floor, Toronto ON, M5G 2L3 Guidelines for the Management of Actionable Incidental Findings in the Lung Cancer Screening Pilot for People at High Risk Dr. Micheal McInnis, Lead, Radiology Quality Assurance, University Health Network Dr. Heidi Schmidt, Clinical Radiology Lead, Lung Cancer Screening Pilot for People at High Risk Michelle Ang (...) , Lead, Radiology Quality Assurance Program, Cancer Imaging Program Resulting Recommendations Summary Table: Actionable Incidental Findings Recommendations in the context of a high risk lung cancer screening population Incidental Finding Sources Consulted Not Actionable Actionable Indeterminate renal nodule or mass (4) 1. Simple renal cysts (-10 - 20 HU), cysts >70 HU, and nodules too small to characterize. Fatty nodules without calcification (angiomyolipomas) RECOMMENDATION: No further evaluation 1

2021 Cancer Care Ontario

11. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial

Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial - PubMed This site needs JavaScript to work properly. Please enable it to take (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Eur J Cancer Actions . 2021 Apr 1;149:14-22. doi: 10.1016/j.ejca.2021.02.019. Online ahead of print. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated

2021 EvidenceUpdates

12. Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines Full Text available with Trip Pro

Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines Redirecting

2021 Integrative medicine research

13. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer T echnology appraisal guidance Published: 10 March 2021 www.nice.org.uk/guidance/ta683 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non- squamous non-small-cell lung cancer (TA683) © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2021 National Institute for Health and Clinical Excellence - Technology Appraisals

14. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations ASCO special articles TherapyforStageIVNon–Small-CellLungCancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Nasser H. Hanna,MD 1 ; Andrew G. Robinson,MD 2 ; Sarah Temin, MSPH 3 ; Sherman Baker Jr, MD 4 ; Julie R. Brahmer,MD 5 ; Peter M. Ellis, MD, PhD 6 ; Laurie E. Gaspar, MD, MBA 7,8 ; Rami Y. Haddad,MD 9 ; Paul J. Hesketh,MD 10 ; Dharamvir Jain,MD 11 ; Ishmael Jaiyesimi,MD 12 ; David H. Johnson, MD (...) , MACP 13 ; Natasha B. Leighl,MD 14 ; Pamela R. Mof?tt 15 ; Tanyanika Phillips,MD 16 ; Gregory J. Riely, MD, PhD 17 ; Rafael Rosell,MD 18 ; Joan H. Schiller,MD 19 ; Bryan J. Schneider,MD 20 ; Navneet Singh, MD, DM 21 ; David R. Spigel,MD 22 ; Joan Tashbar 23 ;and Gregory Masters,MD 24 abstract PURPOSEToprovideevidence-basedrecommendationsupdatingthe2017ASCOguidelineonsystemictherapy for patients with stage IV non–small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic

2021 Cancer Care Ontario

15. Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations

Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | Journal of Clinical Oncology Search in: Menu > > > > Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.03570 Journal of Clinical Oncology - published online before print February 16, 2021 PMID: Therapy for Stage IV (...) Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update , MD 1 x Nasser H. Hanna ; , MD 2 x Andrew G. Robinson ; , MSPH 3 x Sarah Temin ; , MD 4 x Sherman Baker Jr ; , MD 5 x Julie R. Brahmer ; , MD, PhD 6 x Peter M. Ellis ; , MD, MBA 7 , 8 x Laurie E. Gaspar ; , MD 9 x Rami Y. Haddad ; , MD 10 x Paul J. Hesketh ; , MD 11 x Dharamvir Jain ; , MD 12 x Ishmael Jaiyesimi ; , MD, MACP 13 x David H. Johnson ; , MD 14 x Natasha B. Leighl ; 15 x Pamela R. Moffitt

2021 American Society of Clinical Oncology Guidelines

16. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) -small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid, Spain. Electronic address: lpazaresr@seom.org. 2 Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania. 3 Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales

2021 EvidenceUpdates

17. Trilacicilib (Cosela) - To mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer

Trilacicilib (Cosela) - To mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer Drug Approval Package: COSELA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: COSELA Company: G1 Therapeutics, Inc. Application Number: 214200 Approval Date: 2/12/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

2021 FDA - Drug Approval Package

18. Tepotinib (Tepmetko) - To treat non-small cell lung cancer

Tepotinib (Tepmetko) - To treat non-small cell lung cancer Drug Approval Package: TEPMETKO U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TEPMETKO Company: EMD Serono, Inc. Application Number: 214096 Approval Date: 02/03/2021 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2021 FDA - Drug Approval Package

19. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) : Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Jan 29;JCO2003579. doi: 10.1200/JCO.20.03579. Online ahead of print. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized

2021 EvidenceUpdates

20. Lung Cancer: Screening

Lung Cancer: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation to see the latest documents available. Recommendation Summary Population Recommendation Adults Aged 55-80, with a History of Smoking The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 (...) years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. B View the Clinical Summary in Population Asymptomatic adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit smoking within the past 15 years. Recommendation Screen annually for lung cancer with low-dose computed tomography. Discontinue

2021 U.S. Preventive Services Task Force